Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06455293 · ClinicalTrials.gov registry record · Phase 2
Psilocybin Therapy for Depression in Parkinson's Disease
A Phase 2 study of Depression and Parkinson Disease, sponsored by Joshua Woolley, MD, PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06455293 is a Phase 2 study of Depression and Parkinson Disease that is actively recruiting participants, run by Joshua Woolley, MD, PhD. The registered enrollment target is 60 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06455293, a Phase 2 study of Depression and Parkinson Disease, is actively recruiting participants, sponsored by Joshua Woolley, MD, PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06455293
The ClinicalTrials.gov registry entry for NCT06455293 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The listed sponsor is Joshua Woolley, MD, PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT06455293 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06455293 about?
NCT06455293 is a clinical study titled "Psilocybin Therapy for Depression in Parkinson's Disease". The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
What is the current status of trial NCT06455293?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-08-19. Estimated completion is 2028-06.
What conditions does trial NCT06455293 study?
This clinical trial studies the following conditions: Depression, Parkinson Disease.
What interventions are being tested in trial NCT06455293?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06455293?
This trial is sponsored by Joshua Woolley, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06455293 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.